We are live on ! Find out more
CAM

Cormorant Asset Management Portfolio holdings

AUM $1.99B
1-Year Est. Return 737.95%
This Fund
S&P 500
This Quarter Est. Return
+0.54%
1 Year Est. Return
+737.95%
3 Year Est. Return
+5,256.52%
5 Year Est. Return
+13,483.26%
10 Year Est. Return
+564,575.55%
AUM
$2.46B
AUM Growth
-$483M
Cap. Flow
-$259M
Cap. Flow %
-10.54%
Top 10 Hldgs %
47.28%
Holding
112
New
8
Increased
8
Reduced
35
Closed
24

Top Buys

Rank Stock Value
1
ERAS icon
Erasca
ERAS
+$217M
2
IMRX icon
Immuneering
IMRX
+$60.5M
3
TNGX icon
Tango Therapeutics
TNGX
+$37.1M
4
CYTK icon
Cytokinetics
CYTK
+$29.4M
5
TYRA icon
Tyra Biosciences
TYRA
+$20.4M

Top Sells

Rank Stock Value
1
AVIR icon
Atea Pharmaceuticals
AVIR
+$41.1M
2
TWST icon
Twist Bioscience
TWST
+$24.7M
3
XLRN
Acceleron Pharma
XLRN
+$22M
4
MASS icon
908 Devices
MASS
+$21.1M
5
TPTX
Turning Point Therapeutics, Inc. Common Stock
TPTX
+$13.9M

Sector Composition

Rank Sector Weight
1 Healthcare 99.61%
2 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
DTIL icon
76
Precision BioSciences
DTIL
$207M
$4M 0.16%
11,551
– –
DNTH icon
77
Dianthus Therapeutics
DNTH
$6.09B
$3.48M 0.14%
29,888
– –
LENZ
78
LENZ Therapeutics
LENZ
$168M
$3.26M 0.13%
29,022
– –
SRNE
79
DELISTED
Sorrento Therapeutics, Inc.
SRNE
$3.05M 0.12%
400,000
-100,000
-20% -$848K
AUTL
80
Autolus Therapeutics
AUTL
$562M
$2.57M 0.1%
392,167
– –
GOSS icon
81
Gossamer Bio
GOSS
$87M
$2.49M 0.1%
198,382
– –
QTNT
82
DELISTED
Quotient Limited Ordinary Shares
QTNT
$2.34M 0.1%
25,000
-5,083
-17% -$635K
BCEL
83
DELISTED
Atreca, Inc. Class A Common Stock
BCEL
$1.7M 0.07%
273,500
– –
ORTX
84
DELISTED
Orchard Therapeutics plc American Depositary Shares
ORTX
$590K 0.02%
25,665
– –
XFOR icon
85
X4 Pharmaceuticals
XFOR
$460M
$550K 0.02%
3,466
– –
IMV
86
DELISTED
IMV Inc. Common Shares
IMV
$385K 0.02%
23,437
– –
NERV icon
87
Minerva Neurosciences
NERV
$199M
$167K 0.01%
11,968
-18,750
-61% -$282K
OTLKW
88
DELISTED
Outlook Therapeutics, Inc. Series A Warrant Expiring 02/18/2022
OTLKW
$54K ﹤0.01%
270,698
-145,968
-35% -$39.6K
ARKG icon
89
PUT
ARK Genomic Revolution ETF
ARKG
$1.73B
– –
-750,000
Closed -$69.4M
ARKK icon
90
PUT
ARK Innovation ETF
ARKK
$6.31B
– –
-500,000
Closed -$65.4M
CCCC icon
91
C4 Therapeutics
CCCC
$412M
– –
-354,495
Closed -$13.4M
CRDF icon
92
Cardiff Oncology
CRDF
$77.2M
– –
-95,720
Closed -$637K
INSM icon
93
Insmed
INSM
$28.6B
– –
-250,000
Closed -$7.12M
IWM icon
94
PUT
iShares Russell 2000 ETF
IWM
$83B
– –
-1,000,000
Closed -$229M
MASS icon
95
908 Devices
MASS
$364M
– –
-545,320
Closed -$21.1M
NUVB.WS
96
DELISTED
Nuvation Bio Inc Warrants
NUVB.WS
– –
-83,332
Closed -$217K
OBIO icon
97
Orchestra BioMed
OBIO
$254M
– –
-240,000
Closed -$2.45M
OMER icon
98
CALL
Omeros
OMER
$959M
– –
-1,000,000
Closed -$14.8M
RPTX
99
DELISTED
Repare Therapeutics
RPTX
– –
-363,766
Closed -$11.3M
SPRY icon
100
ARS Pharmaceuticals
SPRY
$612M
– –
-239,099
Closed -$7.39M
1 2 3
4
5

Similar funds

SC
Syon Capital San Francisco, California $1.99B AUM 22.67% 1-Year Est. Return
RMCM
Reynders McVeigh Capital Management Boston, Massachusetts $1.98B AUM 23.37% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.79% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
MYAM
Meiji Yasuda Asset Management Tokyo, Japan $2B AUM 22.52% 1-Year Est. Return
C
Consulta London, United Kingdom $2.01B AUM 16.82% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BGM
Burkehill Global Management New York $2.02B AUM 85.32% 1-Year Est. Return

Cormorant Asset Management's Q3 2021 Portfolio in Review

As of Q3 2021, Cormorant Asset Management held 112 positions worth $2.46B, down 16% from $2.94B the previous quarter. Its ten largest holdings account for 47% of the portfolio.

Cormorant Asset Management withdrew a net $259M in Q3 2021, closing 24 positions and reducing 35 holdings. Its most notable exit was Twist Bioscience, an estimated $24.7M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 86% a quarter earlier, followed by Financials.

Against the trend, Cormorant Asset Management opened a new position in Erasca worth $217M.

  • Cormorant Asset Management's largest Q3 2021 buy was Erasca: 10,505,550 shares worth $217M.
  • Cormorant Asset Management added most to Tango Therapeutics in Q3 2021, an estimated $37.1M increase.
  • Cormorant Asset Management's biggest Q3 2021 reduction was Atea Pharmaceuticals, cutting an estimated $41.1M.
  • Cormorant Asset Management fully exited Twist Bioscience in Q3 2021, selling an estimated $24.7M.
  • Cormorant Asset Management's ten largest holdings make up 47% of its $2.46B portfolio in Q3 2021.
  • Cormorant Asset Management opened 8 new positions and closed 24 in Q3 2021.
  • Cormorant Asset Management's portfolio value fell 16% quarter-over-quarter to $2.46B.

Based on Cormorant Asset Management's 13F filing for Q3 2021, filed 15 Nov 2021.